A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants

• Status: Completed
• Trial end date: 2001-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their infants can help reduce the chance that a mother will give HIV to her baby during delivery.

NVP is a promising medication for blocking HIV transmission from HIV-positive mothers to their infants. NVP is inexpensive and is easily absorbed by the mother and transferred to the infant. It is thought that even a single dose to the mother and infant may provide enough protection to the baby during the time of exposure to HIV at birth.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Nevirapine

Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are an HIV-positive pregnant woman.

• Have been pregnant for at least 28 weeks.

• Are at least 13 years of age (consent of parent or guardian is required if under 18).

Exclusion Criteria

You will not be eligible for this study if:

• You intend to breast-feed.

• You are allergic to benzodiazepines (a type of tranquilizer).

• You have a liver disorder.

• You have received nonnucleoside reverse transcriptase inhibitors (NNRTIs), a class of anti-HIV drugs.

• You refuse to take ZDV.